Literature DB >> 17035369

The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan.

Ichiro Hirahara1, Makoto Inoue, Kousuke Okuda, Yasuhiro Ando, Shigeaki Muto, Eiji Kusano.   

Abstract

BACKGROUND: Long-term peritoneal dialysis (PD) leads to peritoneal injury. At worst, peritoneal injury leads to encapsulating peritoneal sclerosis (EPS), which is a serious complication of PD. The mortality rate of EPS is extremely high. To perform PD safely, monitoring of peritoneal injury that leads to EPS is a necessity.
METHODS: A total of 444 PD patients with end-stage renal disease at 60 centres in Japan were analysed (sex, 54% males; median age, 56 years; median PD duration, 55 months). Matrix metalloproteinase (MMP)-2 and MMP-9 in the peritoneal effluents were analysed with gelatin zymography or enzyme-linked immunosorbent assay. Cells expressing MMP-2 in the peritoneal tissue were investigated immunohistologically with anti-MMP-2 antibodies. Peritoneal solute transport was assessed with the peritoneal equilibration test (PET).
RESULTS: The MMP-2 levels in peritoneal effluents obtained with the PET were significantly correlated with the D/P Cr ratio (R = 0.69, P < 0.001) and the D/D0 glucose ratio (R = -0.59, P < 0.001). The MMP-2 levels in patients with mild peritoneal injury, moderate peritoneal injury, severe peritoneal injury (EPS) and infectious peritonitis were significantly higher than those in control patients (P < 0.001, P < 0.001, P < 0.01 and P < 0.05, respectively). MMP-2 was produced by myofibroblast-like mesenchymal cells and macrophages in the peritoneum. The peritoneal effluents from patients with infectious peritonitis showed strong MMP-9 signals.
CONCLUSIONS: From these results, MMP-2 levels in peritoneal effluents reflect peritoneal solute transport and changes in MMP-2 levels are associated with peritoneal injury that leads to EPS. MMP-2 may be a useful marker of peritoneal injury, increased solute transport or progression to EPS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035369     DOI: 10.1093/ndt/gfl566

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  26 in total

1.  Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?

Authors:  Deirisa Lopes Barreto; Annemieke M Coester; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2013-09-01       Impact factor: 1.756

2.  Abatacept as a therapeutic option in the treatment of encapsulated peritoneal sclerosis: an experimental rat model.

Authors:  Latife Bircan; Suleyman Karakose; Hatice Unverdi; Ayşe Zeynep Bal; Selman Unverdi; Murat Duranay
Journal:  Int Urol Nephrol       Date:  2017-02-11       Impact factor: 2.370

3.  The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis.

Authors:  Bülent Huddam; Murat Başaran; Gülay Koçak; Alper Azak; Funda Yalçın; Nihan Haberal Reyhan; Murat Duranay
Journal:  Int Urol Nephrol       Date:  2015-07-10       Impact factor: 2.370

Review 4.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

5.  Dialysate cytokine levels do not predict encapsulating peritoneal sclerosis.

Authors:  Catriona Goodlad; Frederick W K Tam; Sohail Ahmad; Gurjeet Bhangal; Bernard V North; Edwina A Brown
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

6.  Matrix metalloproteinase 9 is associated with peritoneal membrane solute transport and induces angiogenesis through β-catenin signaling.

Authors:  Manreet Padwal; Imad Siddique; Lili Wu; Katelynn Tang; Felix Boivin; Limin Liu; Jennifer Robertson; Darren Bridgewater; Judith West-Mays; Azim Gangji; Kenneth Scott Brimble; Peter J Margetts
Journal:  Nephrol Dial Transplant       Date:  2017-01-01       Impact factor: 5.992

7.  Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?

Authors:  Utpal Sen; Suresh C Tyagi
Journal:  PPAR Res       Date:  2010-06-29       Impact factor: 4.964

8.  Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.

Authors:  Utpal Sen; Walter E Rodriguez; Neetu Tyagi; Munish Kumar; Soumi Kundu; Suresh C Tyagi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-09       Impact factor: 4.310

Review 9.  Peritoneal changes in patients on long-term peritoneal dialysis.

Authors:  Raymond T Krediet; Dirk G Struijk
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

10.  Periostin: a matricellular protein involved in peritoneal injury during peritoneal dialysis.

Authors:  Niko Braun; Kontheari Sen; M Dominik Alscher; Peter Fritz; Martin Kimmel; Johann Morelle; Eric Goffin; Achim Jörres; Rudolf P Wüthrich; Clemens D Cohen; Stephan Segerer
Journal:  Perit Dial Int       Date:  2013-02-01       Impact factor: 1.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.